Noxopharm Ltd has released a press release.
Appendix 4E and Audited Financial Statements
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Noxopharm
- June 2023 Activities Report and Appendix 4C
- IONIC Trial Abstract Published at ASCO
- Study results show new Sofra drug reduces inflammation
- March 2023 Quarterly Activities Report and Appendix 4C
- Noxopharm to Prioritise Cutting-Edge Chroma & Sofra Programs
Later from Noxopharm
- Latest CRO-67 data shows success in reducing cancer growth
- Pause in Trading
- Trading Halt
- US FDA grants Orphan Drug Designation for CRO-67
- Response to ASX Query
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm